Read more about the article BioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company’s lead project – BL-8040; Sufficient funds to support this development; Stock price target raised to NIS 5.15

BioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company’s lead project – BL-8040; Sufficient funds to support this development; Stock price target raised to NIS 5.15

Continue ReadingBioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company’s lead project – BL-8040; Sufficient funds to support this development; Stock price target raised to NIS 5.15
Read more about the article BioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged.

BioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged.

Continue ReadingBioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged.
Read more about the article BiolineRX is on track with its execution of multiple clinical development programs for the Company’s lead product – BL-8040; the company has sufficient cash until H1-2020; target price remains unchanged as company’s clinical development is in line with our expectations

BiolineRX is on track with its execution of multiple clinical development programs for the Company’s lead product – BL-8040; the company has sufficient cash until H1-2020; target price remains unchanged as company’s clinical development is in line with our expectations

Continue ReadingBiolineRX is on track with its execution of multiple clinical development programs for the Company’s lead product – BL-8040; the company has sufficient cash until H1-2020; target price remains unchanged as company’s clinical development is in line with our expectations